New Launch18 Feb 2025, 08:24 pm
Everest Organics LTD. Obtains Korea Drug Master File (KDMF) Approval for Rabeprazole Sodium API
AI Summary
Everest Organics Limited has announced the successful acquisition of Korea Drug Master File (KDMF) approval for its Rabeprazole Sodium API in February 2025. The Rabeprazole Sodium API is primarily used to treat conditions related to excessive stomach acid production, such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. As a proton pump inhibitor (PPI), it significantly reduces the amount of acid produced in the stomach, promoting the healing of ulcers and alleviating symptoms like heartburn and acid reflux. This approval allows the Company to export its Rabeprazole Sodium API to the South Korean market.
Key Highlights
- Everest Organics LTD. obtains Korea Drug Master File (KDMF) approval for Rabeprazole Sodium API
- Rabeprazole Sodium API is used to treat conditions related to excessive stomach acid production
- Proton pump inhibitor (PPI) significantly reduces the amount of acid produced in the stomach
- Approval allows the Company to export Rabeprazole Sodium API to the South Korean market
- Achievement marks a significant milestone in the Company's growth and expansion strategy